Articles related to TYPE 2 DIABETES

The study was conducted while GLP-1 RAs and SGLT-2 inhibitors were still considered second-line therapies; however, in a 2022 Consensus Report, the American Diabetes Association and the European Association for the Study of Diabetes recommended these medications as first-line therapy for people with type 2 diabetes who have or are at high risk of certain complications such as heart failure, CKD, and atherosclerotic cardiovascular disease (ASCVD). Are the medications’ price tag keeping people away?

This 28-year-old man with hypertension and diabetes works two jobs, says he does not have time to exercise, takes most of his meals from fast-food restaurants, and is unhappy with his lifestyle. What would you recommend?

A study of nearly 10,000 adults aged 65 and older found that individuals with either complete tooth loss or diabetes had accelerated cognitive decline compared to those without the diseases. And decline was fastest for individuals 65-84 who had both conditions. The authors hypothesize a combination of nutritional deficiency and inflammation as playing a role.

Whether prescribing them for diabetes or weight loss, what factors should you consider when choosing among the seven approved GLP-1 agonist formulations? This concise review highlights the variables.

The results of these trials show that vitamin D reduced the risk of diabetes progression by 3% to 18% after three years, with serum 25-hydroxy D levels of at least 125 nmol/L showing the greatest benefit. Vitamin D was also associated with a 30% increase in the likelihood of returning to normal glucose regulation.

The SGLT2 inhibitor bexagliflozin is now available under the brand name Brenzavvy. Approval was based on monotherapy trials versus glimepiride, where the new drug was non-inferior, and in combination with metformin.